

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7223503

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	06/03/2021

CONVEYING PARTY DATA

Name	Execution Date
ANTIBE AMALCO INC.	06/03/2021
ANTIBE THERAPEUTICS INC.	06/03/2021

RECEIVING PARTY DATA

Name:	ANTIBE THERAPEUTICS INC.
Street Address:	15 PRINCE ARTHUR AVENUE
City:	TORONTO
State/Country:	CANADA
Postal Code:	M5R 1B2

PROPERTY NUMBERS Total: 3

Property Type	Number
Patent Number:	7910568
Patent Number:	7879827
Patent Number:	8114857

CORRESPONDENCE DATA

Fax Number: (403)265-7219

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4032983100

Email: docketing-patentscalgary@bennettjones.com

Correspondent Name: IRENE T. BRIDGER, BENNETT JONES LLP

Address Line 1: 4500 BANKERS HALL EAST, 855 - 2ND STREET SW

Address Line 4: CALGARY, CANADA T2P 4K7

ATTORNEY DOCKET NUMBER:	54688-34-81-87
NAME OF SUBMITTER:	IRENE T. BRIDGER
SIGNATURE:	/Irene T. Bridger/
DATE SIGNED:	03/14/2022

Total Attachments: 14

source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page1.tif

source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page2.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page3.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page4.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page5.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page6.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page7.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page8.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page9.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page10.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page11.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page12.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page13.tif
source=4-(FILED) Articles of Amalgamation - Antibe Therapeutics Inc. - filed on June 3 2021#page14.tif

Section 4 The Directors is/are:

First name, middle names and surname	Address for Service	Resident Canadian
John Wallace	110 Bloor Street West, Suite 1409 Toronto, ON M5S 2W7	Yes
Daniel Legault	276 MacPherson Avenue Toronto, ON M4V 1A3	Yes
Walt Macnee	71 Chestnut Park Road Toronto, ON M4W 1W7	Yes
Roderick Flower	14 Whitehill Bradford-on-Avon, Wiltshire, UK BA15 1SG	No
Amal Khouri	3400 De Maisonneuve Blvd W. Montreal, QC H3Z 3B8	Yes
Yung Wu	468 Wellington Street West, Suite 601 Toronto, ON M5V 1E3	Yes
Robert Hoffman	14637 Arroyo Hondo San Diego, CA USA 92127	No
Jennifer McNealey	762 Marin Drive Mill Valley, CA USA 94941	No

5. Method of amalgamation, check A or B
 Méthode choisie pour la fusion – Cocher A ou B :

A - Amalgamation Agreement / Convention de fusion :

The amalgamation agreement has been duly adopted by the shareholders of each of the amalgamating corporations as required by subsection 176 (4) of the *Business Corporations Act* on the date set out below.

Les actionnaires de chaque société qui fusionne ont dûment adopté la convention de fusion conformément au paragraphe 176(4) de la *Loi sur les sociétés par actions* à la date mentionnée ci-dessous.

or
ou

B - Amalgamation of a holding corporation and one or more of its subsidiaries or amalgamation of subsidiaries / Fusion d'une société mère avec une ou plusieurs de ses filiales ou fusion de filiales :

The amalgamation has been approved by the directors of each amalgamating corporation by a resolution as required by section 177 of the *Business Corporations Act* on the date set out below.

Les administrateurs de chaque société qui fusionne ont approuvé la fusion par voie de résolution conformément à l'article 177 de la *Loi sur les sociétés par actions* à la date mentionnée ci-dessous.

The articles of amalgamation in substance contain the provisions of the articles of incorporation of
 Les statuts de fusion reprennent essentiellement les dispositions des statuts constitutifs de

Antibe Therapeutics Inc.

and are more particularly set out in these articles.
 et sont énoncés textuellement aux présents statuts.

Names of amalgamating corporations Dénomination sociale des sociétés qui fusionnent	Ontario Corporation Number Numéro de la société en Ontario	Date of Adoption/Approval Date d'adoption ou d'approbation		
		Year année	Month mois	Day jour
Antibe Therapeutics Inc.	002205405	2021	06	03
Antibe Amalco Inc.	005050332	2021	06	03

6. Restrictions, if any, on business the corporation may carry on or on powers the corporation may exercise.
Limites, s'il y a lieu, imposées aux activités commerciales ou aux pouvoirs de la société.

None.

7. The classes and any maximum number of shares that the corporation is authorized to issue:
Catégories et nombre maximal, s'il y a lieu, d'actions que la société est autorisée à émettre :

The Corporation is authorized to issue an unlimited number of common shares.

8. Rights, privileges, restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series:

Droits, privilèges, restrictions et conditions, s'il y a lieu, rattachés à chaque catégorie d'actions et pouvoirs des administrateurs relatifs à chaque catégorie d'actions qui peut être émise en série :

None.

9. The issue, transfer or ownership of shares is/are not restricted and the restrictions (if any) are as follows:
L'émission, le transfert ou la propriété d'actions est/n'est pas restreint. Les restrictions, s'il y a lieu, sont les suivantes :

None.

10. Other provisions, (if any):
Autres dispositions, s'il y a lieu :

None.

11. The statements required by subsection 178(2) of the *Business Corporations Act* are attached as Schedule "A".
Les déclarations exigées aux termes du paragraphe 178(2) de la *Loi sur les sociétés par actions* constituent l'annexe A.

12. A copy of the amalgamation agreement or directors' resolutions (as the case may be) is/are attached as Schedule "B".
Une copie de la convention de fusion ou les résolutions des administrateurs (selon le cas) constitue(nt) l'annexe B.

These articles are signed in duplicate.
Les présents statuts sont signés en double exemplaire.

Name and **original signature** of a director or authorized signing officer of each of the amalgamating corporations. Include the name of each corporation, the signatories name and description of office (e.g. president, secretary). **Only a director or authorized signing officer can sign on behalf of the corporation.** / Nom et **signature originale** d'un administrateur ou d'un signataire autorisé de chaque société qui fusionne. Indiquer la dénomination sociale de chaque société, le nom du signataire et sa fonction (p. ex. : président, secrétaire). **Seul un administrateur ou un dirigeant habilité peut signer au nom de la société.**

Antibe Therapeutics Inc.

Names of Corporations / Dénomination sociale des sociétés

By / Par



Daniel Legault

Chief Executive Officer

Signature / Signature


Print name of signatory /
Nom du signataire en lettres moulées

Description of Office / Fonction

Antibe Amalco Inc.

Names of Corporations / Dénomination sociale des sociétés

By / Par



Scott Curtis

Director

Signature / Signature

Print name of signatory /
Nom du signataire en lettres moulées

Description of Office / Fonction

Names of Corporations / Dénomination sociale des sociétés

By / Par

Signature / Signature

Print name of signatory /
Nom du signataire en lettres moulées

Description of Office / Fonction

Names of Corporations / Dénomination sociale des sociétés

By / Par

Signature / Signature

Print name of signatory /
Nom du signataire en lettres moulées

Description of Office / Fonction

Names of Corporations / Dénomination sociale des sociétés

By / Par

Signature / Signature

Print name of signatory /
Nom du signataire en lettres moulées

Description of Office / Fonction

ARTICLES OF AMALGAMATION

SCHEDULE "A"


[see attached]

**STATEMENT OF DIRECTOR OR OFFICER
PURSUANT TO SUBSECTION 178(2) OF
THE BUSINESS CORPORATIONS ACT (ONTARIO)**

I, Scott Curtis, of the City of Toronto, Province of Ontario, hereby certify and state as follows:

1. This Statement is made pursuant to subsection 178(2) of the *Business Corporations Act*.
2. I am a Director of Antibe Amalco Inc. (the "Amalgamating Corporation"), which is amalgamating with Antibe Therapeutics Inc. (the "Amalgamation") to continue as Antibe Therapeutics Inc. (the "Amalgamated Corporation") and as such have knowledge of the Amalgamating Corporations affairs.
3. I have conducted such examination of the books and records of the Amalgamating Corporation as are necessary to enable me to make the statements hereinafter set forth.
4. There are reasonable grounds for believing that:
 - (i) the Amalgamating Corporation is and the Amalgamated Corporation will be able to pay its liabilities as they become due; and
 - (ii) the realizable value of the assets of the Amalgamated Corporation will not be less than the aggregate of its liabilities and stated capital of all classes.
5. There are reasonable grounds for believing that no creditor of the Amalgamating Corporation will be prejudiced by the amalgamation.

DATED as of the 3rd day of June, 2021.




Scott Curtis
Antibe Amalco Inc.

**STATEMENT OF DIRECTOR OR OFFICER
PURSUANT TO SUBSECTION 178(2) OF
THE BUSINESS CORPORATIONS ACT (ONTARIO)**

I, Daniel Legault, of the City of Toronto, Province of Ontario, hereby certify and state as follows:

1. This Statement is made pursuant to subsection 178(2) of the *Business Corporations Act*.
2. I am an officer of Antibe Therapeutics Inc. (the "Amalgamating Corporation"), which is amalgamating with Antibe Amalco Inc. (the "Amalgamation") to continue as Antibe Therapeutics Inc. (the "Amalgamated Corporation") and as such have knowledge of the Amalgamating Corporation's affairs.
3. I have conducted such examination of the books and records of the Amalgamating Corporation as are necessary to enable me to make the statements hereinafter set forth.
4. There are reasonable grounds for believing that:
 - (i) the Amalgamating Corporation is and the Amalgamated Corporation will be able to pay its liabilities as they become due; and
 - (ii) the realizable value of the assets of the Amalgamated Corporation will not be less than the aggregate of its liabilities and stated capital of all classes.
5. There are reasonable grounds for believing that no creditor of the Amalgamating Corporation will be prejudiced by the amalgamation.

DATED as of the 3rd day of June, 2021.



Daniel Legault
Antibe Therapeutics Inc.

ARTICLES OF AMALGAMATION

SCHEDULE "B"

[Director's Resolution - See attached]

RESOLUTIONS OF THE BOARD OF DIRECTORS
OF
ANTIBE AMALCO INC.
(the "Corporation")

AMALGAMATION


WHEREAS the Corporation wishes to amalgamate with Antibe Therapeutics Inc. pursuant to Section 177(1) of the *Business Corporations Act* (Ontario).

NOW THEREFORE BE IT RESOLVED THAT:

1. The sole director of the Corporation hereby authorized and approved the amalgamation between the Corporation and Antibe Therapeutics Inc. on the following terms:
 - (a) the shares of the Corporation shall be cancelled upon amalgamation, without any repayment of capital in respect thereof;
 - (b) the by-laws of the amalgamated corporation shall be the same as the by-laws of Antibe Therapeutics Inc.;
 - (c) the articles of amalgamation shall be the same as the articles of Antibe Therapeutics Inc.; and
 - (d) no securities shall be issued and no assets shall be distributed by the amalgamated corporation in connection with the amalgamation.
2. Any one director or officer of the Corporation is hereby authorized and directed to do, sign and execute, whether under the corporate seal of the Corporation or otherwise, all articles of amalgamation, deeds, agreements, documents and things necessary or desirable to give effect to the foregoing.
3. These resolutions may be signed and delivered in any number of counterparts (including by facsimile, email or other electronic transmission), each of which when executed shall be deemed to be an original and all of which together shall constitute one and the same instrument, and that the different directors of the Board need not be signatories to the same counterpart.

The foregoing resolutions are, by the signature below of the sole director of the Corporation, each passed by the Board of Directors of the Corporation pursuant to the provisions of Section 129(1) of the *Business Corporations Act* (Ontario).

DATED as of the 3rd day of June, 2021.



SCOTT WILSON CURTIS

**RESOLUTIONS OF THE BOARD OF DIRECTORS
OF
ANTIBE THERAPEUTICS INC.
(the "Corporation")**

AMALGAMATION

WHEREAS the Corporation wishes to amalgamate with Antibe Amalco Inc., a wholly owned subsidiary of the Corporation, pursuant to Section 177(1) of the *Business Corporations Act* (Ontario).


NOW THEREFORE BE IT RESOLVED THAT:

1. The directors of the Corporation hereby authorize and approve the amalgamation between the Corporation and Antibe Amalco Inc. on the following terms:
 - (a) the shares of the Antibe Amalco Inc. shall be cancelled upon amalgamation, without any repayment of capital in respect thereof;
 - (b) the by-laws of the amalgamated corporation shall be the same as the by-laws of the Corporation;
 - (c) the articles of amalgamation shall be the same as the articles of the Corporation; and
 - (d) no securities shall be issued and no assets shall be distributed by the amalgamated corporation in connection with the amalgamation.
2. Any one director or officer of the Corporation is hereby authorized and directed to do, sign and execute, whether under the corporate seal of the Corporation or otherwise, all articles of amalgamation, deeds, agreements, documents and things necessary or desirable to give effect to the foregoing.
3. These resolutions may be signed and delivered in any number of counterparts (including by facsimile, email or other electronic transmission), each of which when executed shall be deemed to be an original and all of which together shall constitute one and the same instrument, and that the different directors of the Board need not be signatories to the same counterpart.


[The remainder of this page has been left intentionally blank]

The foregoing resolutions are, by the signatures below of all of the directors of the Corporation, each passed by the Board of Directors of the Corporation pursuant to the provisions of Section 129(1) of the *Business Corporations Act* (Ontario).


DATED as of the 3rd day of June, 2021.


John L. Wallace (Jun 1, 2021 12:24 EDT)

JOHN WALLACE


Dan Legault (Jun 1, 2021 13:25 EDT)


DAN LEGAULT


Walt Macnee (Jun 1, 2021 12:11 EDT)


WALT MACNEE


Rod Flower (Jun 1, 2021 17:15 GMT+3)


RODERICK FLOWER


Amal Khouri (Jun 1, 2021 13:04 EDT)

AMAL KHOURI


Yung Wu (Jun 1, 2021 20:23 EDT)

YUNG WU


Robert E. Hoffman (Jun 1, 2021 15:50 PDT)

ROBERT HOFFMAN


Jennifer McNealey (Jun 2, 2021 09:08 PDT)

JENNIFER MCNEALEY